Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers
Conditions: Colorectal Carcinoma; Gastric Adenocarcinoma; Esophageal and GEJ Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma Interventions: Drug: tucatinib; Drug: trastuzumab; Drug: oxaliplatin; Drug: leucovorin; Drug: fluorouracil Sponsor: Seattle Genetics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Cholangiocarcinoma | Eloxatin | Gastroenterology | Genetics | HER2 | Herceptin | Research